Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

7.900 -0.270 (-3.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 159,268
Open 7.930
Bid (Size) 7.870 (1)
Ask (Size) 7.900 (2)
Prev. Close 8.170
Today's Range 7.570 - 8.230
52wk Range 5.830 - 26.25
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rosen Law Firm Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO
From The Rosen Law Firm, P.A.
Via Business Wire
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026. 
Via Benzinga

Performance

YTD
-12.3%
-12.3%
1 Month
+12.7%
+12.7%
3 Month
-12.1%
-12.1%
6 Month
-53.3%
-53.3%
1 Year
-56.5%
-56.5%

More News

Read More
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
From Zenas BioPharma
Via GlobeNewswire
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
StandardAero Surges In Market Debut
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Week In Review: Zenas Raises $259 Million In IPO
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
From Zenas BioPharma
Via GlobeNewswire
Trio Of Biotech IPOs Climb In Debut
Via Talk Markets

Frequently Asked Questions

Is Zenas BioPharma, Inc. - Common Stock publicly traded?
Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
What is the current price of Zenas BioPharma, Inc. - Common Stock?
The current price of Zenas BioPharma, Inc. - Common Stock is 7.900
When was Zenas BioPharma, Inc. - Common Stock last traded?
The last trade of Zenas BioPharma, Inc. - Common Stock was at 03/31/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.